Vanda Pharmaceuticals, Inc. (VNDA)
4.63
-0.18
(-3.74%)
USD |
NASDAQ |
Oct 02, 16:00
4.625
0.00 (0.00%)
After-Hours: 20:00
Vanda Pharmaceuticals Enterprise Value : 132.61M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 132.61M |
| October 01, 2026 | 143.49M |
| September 30, 2026 | 149.53M |
| September 29, 2026 | 156.79M |
| September 28, 2026 | 165.25M |
| September 25, 2026 | 158.00M |
| September 24, 2026 | 153.76M |
| September 23, 2026 | 157.39M |
| September 22, 2026 | 167.67M |
| September 21, 2026 | 164.34M |
| September 18, 2026 | 162.83M |
| September 17, 2026 | 161.62M |
| September 16, 2026 | 154.97M |
| September 15, 2026 | 154.37M |
| September 14, 2026 | 164.04M |
| September 11, 2026 | 160.41M |
| September 10, 2026 | 157.39M |
| September 09, 2026 | 170.09M |
| September 08, 2026 | 174.92M |
| September 04, 2026 | 180.97M |
| September 03, 2026 | 175.53M |
| September 02, 2026 | 187.01M |
| September 01, 2026 | 180.36M |
| August 31, 2026 | 179.16M |
| August 28, 2026 | 172.51M |
| Date | Value |
|---|---|
| August 27, 2026 | 181.57M |
| August 26, 2026 | 176.13M |
| August 25, 2026 | 181.57M |
| August 24, 2026 | 174.92M |
| August 21, 2026 | 171.90M |
| August 20, 2026 | 177.95M |
| August 19, 2026 | 189.43M |
| August 18, 2026 | 181.57M |
| August 17, 2026 | 170.69M |
| August 14, 2026 | 168.27M |
| August 13, 2026 | 156.79M |
| August 12, 2026 | 166.46M |
| August 11, 2026 | 150.74M |
| August 10, 2026 | 156.18M |
| August 07, 2026 | 154.97M |
| August 06, 2026 | 161.93M |
| August 05, 2026 | 160.41M |
| August 04, 2026 | 174.92M |
| August 03, 2026 | 168.88M |
| July 31, 2026 | 161.02M |
| July 30, 2026 | 165.86M |
| July 29, 2026 | 158.00M |
| July 28, 2026 | 164.65M |
| July 27, 2026 | 168.27M |
| July 24, 2026 | 165.86M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SELLAS Life Sciences Group, Inc. | 2.233B |
| Protagonist Therapeutics, Inc. | 8.285B |
| Sagimet Biosciences, Inc. | 326.51M |
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.51M |
| Revenue (Quarterly) | 50.53M |
| Total Expenses (Quarterly) | 113.04M |
| EPS Diluted (Quarterly) | -1.038 |
| Gross Profit Margin (Quarterly) | 89.02% |
| Profit Margin (Quarterly) | -123.7% |
| Earnings Yield | -99.91% |
| Normalized Earnings Yield | -99.91 |